| Enhancer of Zeste homologue2 (EZH2) is an epigenetic regulator that functions as oncogene in astrocytic tumors. | None |
| Mutating or deleting EZH2 can have both oncogenic and tumor suppressive functions by increasing or decreasing H3K27me3. (Review) | None |
| Data present convincing mechanistic results confirming the oncogenic function of EZH2 related to PRC2 functioning (repression of tumor suppressor genes through H3K27me3) in several biological models. | None |
| Inhibition of EZH2 down-regulates myeloma associated oncogenes and up-regulates microRNAs with potential tumor suppressor functions in multiple myeloma cells. | None |
| EZH2 has prognostic value and may play an oncogenic role in Merkel cell carcinoma. | None |
| MiR-4465 suppressed cancer cells proliferation and metastasis by directly targeting the oncogene EZH2. | None |
| EZH2(Y646X) alters the topology and function of chromatin domains to promote synergistic oncogenic programs. | None |
| Identification of mutations in the PRC2 components EED and SUZ12 in the majority of MPNSTs may imply noncanonical oncogenic activities of the intact component, EZH2, and provide new opportunities for therapeutic intervention. | None |
| The oncogenic function of circ-EZH2 was partly dependent on its modulation of DDAH1 and CBX3.#This is the parental gene. | None |